ArticlePsychopharmacology2013
Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats.
Article in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review.Medicina (Kaunas, Lithuania) · 2019Pooled it
- Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.British journal of pharmacology · 2015Pooled it
- A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide-enriched air breathing challenge.Psychopharmacology · 2025Trial
- Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.Psychopharmacology · 2020Trial
- Medicinal Plants for Major Depressive Disorder.Brain sciences · 2026Review
- Owner-Directed Feline Aggression in Thailand: Characteristics, Associated Factors, and a Clinical Comparison of Treatments.Life (Basel, Switzerland) · 2026Article
- Defensive and Emotional Behavior Modulation by Serotonin in the Periaqueductal Gray.Cellular and molecular neurobiology · 2023Review
- Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety.Psychiatry research communications · 2022Article
- Medicinal Cannabis and Central Nervous System Disorders.Frontiers in pharmacology · 2022Review
- The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids.Journal of the National Cancer Institute. Monographs · 2021Article
- Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research.International journal of molecular sciences · 2021Review
- Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial.Frontiers in psychiatry · 2021Article
- Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews.Psychopharmacology · 2020Article
- Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies.Brain sciences · 2020Review
- The Impact of Feeding Cannabidiol (CBD) Containing Treats on Canine Response to a Noise-Induced Fear Response Test.Frontiers in veterinary science · 2020Article
- Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders.Frontiers in pharmacology · 2020Review
- Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.Frontiers in immunology · 2018Review
- Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.British journal of pharmacology · 2017Review
- The endocannabinoid system as a target for novel anxiolytic drugs.Neuroscience and biobehavioral reviews · 2017Review
- Evidences for the Anti-panic Actions of Cannabidiol.Current neuropharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCannabidiol (CBD) is a non-psychotomimetic constituent of Cannabis sativa plant that promotes antianxiety and anti-panic effects in animal models after acute systemic or intra-dorsal periaqueductal gray (DPAG) administration. However, the effects of CBD repeated administration, and the possible mechanisms involved, in animal models of anxiety- and panic-related responses remain poorly understood.
objectiveThe present study evaluates the role of the serotonergic neurotransmission within the DPAG in the modulation of escape responses of rats chronically treated with CBD.
methodsMale Wistar rats received acute or repeated (5 mg/Kg/daily/21 days) administration of CBD and were submitted to the elevated T-maze (ETM). We also investigated if CBD effects on the ETM depend on facilitation of 5-HT1A-mediated neurotransmission in the DPAG. To this latter aim, we verified if these effects would be prevented by intra-DPAG injection of the 5-HT1A receptor antagonist WAY100635 (0.37 nmol/0.2 μL). Also, we verified, by in vivo microdialysis, if CBD chronic treatment increases serotonin (5-HT) release and, by quantitative polymerase chain reaction, if there are changes in 5HT-1A or 5HT-2C mRNA expression in DPAG.
resultsThe results showed that repeated but not acute peripheral administration of CBD decreases escape responses in the ETM, suggesting a panicolytic effect. This treatment did not change 5HT-1A or 5-HT-2C receptor mRNA expression nor modify serotonin extracellular concentrations in the DPAG. CBD effects were prevented by DPAG injection of the 5-HT1A receptor antagonist.
conclusionsTogether, these findings suggest that repeated treatment with CBD induces anti-panic effects by acting on 5-HT1A receptors in DPAG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.